Skip to content
MarketScale
‹ Back to IndustriesSciences

New Nuclear Reactors Make Progress in U.S. The Permitting Process Still Keeps Us Behind.

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor. The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · ColoradoGeorgiaNuclear EnergyNuclear Reactors
Share

Key takeaways

01

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor.

02

The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of…

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor. The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of SMRs. What recent progress is the U.S. making on new deployment of nuclear reactors and general nuclear energy developments?

Public support for nuclear power in the U.S. is reaching new heights, with a recent Gallup survey revealing that 55% of adults now back the energy source, the highest figure since 2012. With no carbon emissions and greater consistency than renewable sources like wind and solar, nuclear power is increasingly recognized for its reliability, leading the Biden administration to champion nuclear energy, particularly “advanced nuclear” reactors with enhanced safety and efficiency features, as a key strategy in achieving a stable, net-zero emissions future.

Projects and research surrounding deployment of nuclear reactors are gaining traction in the U.S., too, some new and some several years in the making. Colorado, for example, is close to deploying research funds toward nuclear energy projects as part of its “Assess Advanced Energy Solutions in Rural Colorado”. Southern Co.’s Vogtle nuclear project in Georgia, despite being seven years overdue and $16 billion over budget, is also nearing completion and is set to become the largest single power source in the U.S. Although currently no other U.S. company plans a project on Vogtle’s scale, experts suggest this could change with up to five similar reactors potentially being built in the next 35 years.

Still, though, if the U.S. is serious about nuclear energy adoption, certain red tape will need to get cut for getting new sites developed and in time to meet the country’s and world’s climate goals. Sarah Kurtz, professor at UC Merced’s School of Engineering and a renowned next-gen energy researcher and expert, gives her analysis of the current conversations surrounding nuclear energy’s return and the promise for future deployment of nuclear reactors.

Sarah’s Thoughts on Development of U.S. Nuclear Reactors 

“In my class this semester, we had debates about nuclear power with opinions ranging from no way to nuclear is a great option. We found that the promises made for the new small modular nuclear reactors are like a dream come true. No worry of a meltdown, hazardous waste reduced or eliminated, lower costs by being assembled cookie cutter fashion, much like prefab houses. So is this hype or is it real?

Small modular reactors are progressing at a snail’s pace in the U.S., but China has already one operating and a second planned. China is also implementing this technology in developing countries like Argentina. In the U.S., the permitting process effectively blocks nuclear. In developing countries, the need for reliable power enables permitting and a much shorter timeline. From what I’ve read, China’s likely to be a leader with small modular reactors.

I expect that not all of the promises will be realized, but small modular nuclear reactors are making good progress. While large scale nuclear is stalled in the U.S., alongside of solar and wind, small nuclear reactors are worth looking at for the future. There’s a snag or problem with every energy solution, but together the solutions we have on the table can deliver a much better world than what we have today. We have to stop being against the things we aren’t 100% for.”

Article written by Daniel Litwin.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512